PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i6.12907ArticleThrombotic Thrombocytopenic Purpura Induced by Combined Toripalimab and Pazopanib Therapy in a Patient with Renal Cell Carcinoma and Vertebral Metastasis: A Case Reporthttps://artdesignp.com/journal/PAR/9/6/10.26689/par.v9i6.12907ZhuQi,XiongBin,LiuDongmei,JinZhengxu,ZhouYujie,ChenXinrong,TianWenji2025962025-12-08Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening form of thrombotic microangiopathy, primarily caused by a deficiency of ADAMTS-13 activity. Immune-related adverse events (irAEs) are autoimmune toxicities mediated by the use of immune checkpoint inhibitors (ICIs).  Here, the study reports a case of thrombotic thrombocytopenic purpura that developed in a patient with renal cell carcinoma and vertebral metastasis following combined treatment with Toripalimab and Pazopanib. The patient received Toripalimab in combination with Pazopanib after undergoing radical nephrectomy for right renal cell carcinoma. Five days later, a generalized erythematous rash appeared, partly confluent, accompanied by congestion and swelling of both palpebral and bulbar conjunctiva. Based on the clinical presentation and laboratory results showing thrombocytopenia and hemolytic anemia, the diagnosis of TTP was established. The condition was considered an adverse effect associated with the combination therapy of Toripalimab and Pazopanib. Plasma exchange and high-dose intravenous immunoglobulin therapy were promptly initiated. The treatment regimen was subsequently modified to Axitinib combined with radiotherapy, leading to a gradual recovery of platelet counts. This report highlights the potential risk of TTP associated with combined ICI and TKI therapy, and underscores the importance of early recognition and timely management of this potentially fatal complication.

Tang B, Chi Z, Guo J, 2020, Toripalimab for the Treatment of Melanoma. Expert Opinion on Biological Therapy, 20(8): 863–869.

Wongvibulsin S, Pahalyants V, Kalinich M, et al., 2022, Epidemiology and Risk Factors for the Development of Cutaneous Toxicities in Patients Treated with Immune-Checkpoint Inhibitors: A United States Population-Level Analysis. Journal of the American Academy of Dermatology, 86(3): 563–572.

Petrelli F, Ardito R, Borgonovo K, et al., 2018, Haematological Toxicities with Immunotherapy in Patients with Cancer: A Systematic Review and Meta-analysis. European Journal of Cancer, 103: 7–16.

Joly B, Coppo P, Veyradier A, 2017, Thrombotic Thrombocytopenic Purpura. Blood, The Journal of the American Society of Hematology, 129(21): 2836–2846.

Berner F, Bomze D, Diem S, et al., 2019, Association of Checkpoint Inhibitor-Induced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncology, 5(7): 1043–1047.

Wang J, Hu X, Jiang S, et al., 2022, Efficacy Analysis of Pazopanib in Metastatic Renal Carcinoma. J Mod Urol, 27(3): 205–209.

Stalder T, Hahn S, Erb P, 1994, Fas Antigen Is the Major Target Molecule for CD4+ T Cell-Mediated Cytotoxicity. Journal of Immunology (Baltimore, Md.: 1950), 152(3): 1127–1133.

Alzahrani M, Alrumaih I, Alhamad F, et al., 2018, Rapid Onset Severe Thrombocytopenia Following Reexposure to Piperacillin-Tazobactam: Report of Two Cases and Review of the Literature. Platelets, 29(6): 628–631.

Lechner K, Obermeier H, 2012, Cancer-Related Microangiopathic Hemolytic Anemia: Clinical and Laboratory Features in 168 Reported Cases. Medicine, 91(4): 195–205.

Felip E, Altorki N, Zhou C, et al., 2021, Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial. The Lancet, 398(10308): 1344–1357.

Eggermont A, Blank C, Mandalà M, et al., 2021, Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Distant Metastasis-Free Survival Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial. The Lancet Oncology, 22(5): 643–654.